IST:ONCSM's PS Ratio is ranked worse than 80.35% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.87
vs IST:ONCSM: 8.09
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS PS Ratio Related Terms
Oncosem Onkolojik Sistemlernayi ve Ticaret AS PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS PS Ratio Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS PS Ratio vs Medical Devices & Instruments Industry
Oncosem Onkolojik Sistemlernayi ve Ticaret AS PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Share Price of today is ₺252.75. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺31.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a PS Ratio of 8.10 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. This is 11% above median its historical median of 7.31. Over the past decade, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PS Ratio has ranged from 1.89 to 12.98. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #646 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 80.3%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PS Ratio too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current PS Ratio of 8.10 is 11% above median its 10-year median of 7.31. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 12.98. The Medical Devices & Instruments industry median PS Ratio is 2.87. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 8.10 is 182.2% above this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #646 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #646 out of 804 companies for PS Ratio. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the lower half of its industry. The industry median PS Ratio is 2.87. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 8.10 is 182.2% above this benchmark. Historically, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's own PS Ratio has ranged from 1.89 to 12.98 over the past decade. While the company's 10-year median is 7.31 vs. the industry median of 2.87, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current PS Ratio of 8.10 is 182.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current PS Ratio is 8.10, which is 11% above median its own 10-year median of 7.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺252.15, compared to a current price of ₺252.75 — trading 0.2% above its estimated fair value. The current PS Ratio is 8.10, which is 11% above median its 10-year median of 7.31 and 182.2% above the Medical Devices & Instruments industry median of 2.87. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current PS Ratio is 8.10 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺252.75 is trading 0.2% above its estimated GF Value™ of ₺252.15.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
PS Ratio: 8.10 (11% above median its 10-year median of 7.31)
GF Value™: ₺252.15 vs. price of ₺252.75 (0.2% above fair value)
Industry Position: 182.2% above the Medical Devices & Instruments median (#646 of 804)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
